| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 03/07/1996 | CA2198462A1 Genetic therapy of diseases caused by the immune system, said therapy using a cell-specific active substance regulated by the cell cycle |
| 03/07/1996 | CA2198345A1 Improvements in production of proteins in host cells |
| 03/07/1996 | CA2198080A1 Cell cycle regulated repressor and dna element |
| 03/07/1996 | CA2197427A1 Gene therapy for transplantation and inflammatory or thrombotic conditions |
| 03/06/1996 | EP0699754A1 Method for diagnosing a predisposition for breast and ovarian cancer |
| 03/06/1996 | EP0699753A2 Protein for the transport of cationic xenobiotic and/or pharmaceutical compounds, DNA sequences coding therefore and its uses |
| 03/06/1996 | EP0699240A1 Gibbon ape leukemia virus-based retroviral vectors |
| 03/06/1996 | EP0699208A1 Novel peptide nucleic acids |
| 03/06/1996 | EP0699079A1 Bioactive and/or targeted dendrimer conjugates |
| 03/06/1996 | EP0699073A1 Allogeneic and xenogeneic transplantation |
| 03/06/1996 | CA2157531A1 Htfiiia gene |
| 03/05/1996 | US5496731 Anti-oncogenes |
| 02/29/1996 | WO1996006188A1 Peptide librairies as a source of syngenes |
| 02/29/1996 | WO1996006177A2 Retrovirus-like particles made non-infectious by a plurality of mutations |
| 02/29/1996 | WO1996006176A1 Functional modified hsv1-tk |
| 02/29/1996 | WO1996006169A1 Human chemokine beta-9 |
| 02/29/1996 | WO1996006168A2 Retinoblastoma protein-interacting zinc finger proteins |
| 02/29/1996 | WO1996006166A1 Improvements in or relating to binding proteins for recognition of dna |
| 02/29/1996 | WO1996006159A1 Unique associated kaposi's sarcoma virus sequences and uses thereof |
| 02/29/1996 | WO1996006111A1 Regulatable elimination of gene expression, gene product function and engineered host cells |
| 02/29/1996 | WO1996006097A1 New multimerizing agents |
| 02/29/1996 | WO1996005866A2 Live vaccine for the treatment of tumour diseases |
| 02/29/1996 | WO1996005856A1 Human chemokine polypeptides |
| 02/29/1996 | WO1996001614A3 Rna component of telomerase |
| 02/29/1996 | WO1996001324A3 Novel internal ribosome entry site, vector containing same and therapeutical use thereof |
| 02/29/1996 | DE4431401A1 Lebendvakzine gegen Tumorerkrankungen Live vaccines against tumors |
| 02/29/1996 | CA2198234A1 Live vaccine for the treatment of tumour diseases |
| 02/29/1996 | CA2198219A1 Human chemokine polypeptides |
| 02/29/1996 | CA2198206A1 Human chemokine beta-9 |
| 02/29/1996 | CA2197890A1 Retinoblastoma protein-interacting zinc finger proteins |
| 02/29/1996 | CA2197864A1 Peptide libraries as a source of syngenes |
| 02/29/1996 | CA2197242A1 Regulatable elimination of gene expression, gene product function and engineered host cells |
| 02/29/1996 | CA2196892A1 Unique associated kaposi's sarcoma virus sequences and uses thereof |
| 02/28/1996 | EP0698665A2 Infectious Tick-Borne Encephalitis virus cDNA clone, recombinant vaccine derived therefrom and preparation thereof |
| 02/28/1996 | EP0698109A1 Gene transfer into pancreatic and biliary epithelial cells |
| 02/28/1996 | EP0698108A1 Adenoviral vectors of animal origin and use thereof in gene therapy |
| 02/28/1996 | EP0698107A1 Gene therapy for haemophilia |
| 02/28/1996 | EP0698092A1 Antisense oligonucleotides which combat aberrant splicing and methods of using the same |
| 02/28/1996 | EP0697893A1 Neural thread protein gene expression and detection of alzheimer's disease |
| 02/28/1996 | EP0697876A1 Xenograft thymus |
| 02/22/1996 | WO1996005321A1 Gene therapy for restenosis using an adenoviral vector |
| 02/22/1996 | WO1996005320A1 Adenovirus comprising a gene coding for glutathion peroxidase |
| 02/22/1996 | WO1996005319A1 Genetically engineered cells that produce dopamine |
| 02/22/1996 | WO1996005309A2 Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| 02/22/1996 | WO1996005308A1 Method for diagnosing a predisposition for breast and ovarian cancer |
| 02/22/1996 | WO1996005307A2 17q-LINKED BREAST AND OVARIAN CANCER SUSCEPTIBILITY GENE |
| 02/22/1996 | WO1996005306A2 IN VIVO MUTATIONS AND POLYMORPHISMS IN THE 17q-LINKED BREAST AND OVARIAN CANCER SUSCEPTIBILITY GENE |
| 02/22/1996 | WO1996005301A1 Novel vesicular acetylcholine carrier |
| 02/22/1996 | WO1996005298A1 Antitumor antisense oligonucleotides |
| 02/22/1996 | WO1996005297A1 Method of gene therapy using dna vectors without selection marker gene |
| 02/22/1996 | WO1996005291A1 Recombinant herpesvirus of turkeys and uses thereof |
| 02/22/1996 | WO1996005221A1 Calcitonin receptor |
| 02/22/1996 | WO1996005218A1 Delivery of nucleic acids |
| 02/22/1996 | WO1996004934A1 Retroviral vectors produced by producer cell lines resistant to lysis by human serum |
| 02/22/1996 | WO1996004932A1 Novel vaccine adjuvant and vaccine |
| 02/22/1996 | WO1996004928A1 Calcitonin gene related peptide receptor |
| 02/22/1996 | WO1996004789A1 A method of selectively destroying neoplastic cells |
| 02/22/1996 | DE4418691A1 3'-(4'-) nicht-radioaktiv markierte Nukleoside und Nukleotide mit Aminocarbonsäure-, Peptid- oder Carbonsäure-Spacer 3 '- (4') non-radioactively labeled nucleosides and nucleotides with aminocarboxylic acid, peptide or carboxylic acid-spacer |
| 02/22/1996 | CA2197497A1 Novel vesicular acetylcholine carrier |
| 02/22/1996 | CA2196208A1 Retroviral vectors produced by producer cell lines resistant to lysis by human serum |
| 02/22/1996 | CA2174232A1 Gene therapy for restenosis using an adenoviral vector |
| 02/20/1996 | US5492314 Preloaded digressive rate mount |
| 02/17/1996 | CA2156132A1 Recombinant vectors derived from adenovirus for use in gene therapy |
| 02/15/1996 | WO1996004397A1 Gene therapy using homologous recombination |
| 02/15/1996 | WO1996004395A1 Recombinant virus vectors |
| 02/15/1996 | WO1996004394A1 Hsv viral vector |
| 02/15/1996 | WO1996004386A1 Method of using transdominant negative retroviral integrase in the treatment of retroviral infection |
| 02/15/1996 | WO1996004384A1 Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression |
| 02/15/1996 | WO1996004383A1 Identification of a human cytomegalovirus gene region involved in down-regulation of mhc class i heavy chain expression |
| 02/15/1996 | WO1996004375A1 Retrovirus-induced osteoclast modulation for osteoporosis therapy |
| 02/15/1996 | WO1996004314A1 Mhc complexes and uses thereof |
| 02/15/1996 | WO1996004295A1 5'-dithio-modified oligonucleotides |
| 02/15/1996 | WO1996003977A1 A liposomal delivery system for biologically active agents |
| 02/15/1996 | WO1996003875A1 Compositions for targeting materials to cells containing androgen receptors |
| 02/15/1996 | WO1996000586A3 Methods for treating cell proliferative disorders by modulating signal transduction |
| 02/15/1996 | WO1995032285A3 Transgenic arthritic mice |
| 02/15/1996 | DE4428402A1 Gentherapeutisches Verfahren unter Verwendung von DNA-Vektoren ohne Selektionsmarker-Gen Gene therapy methods using DNA vectors without selectable marker gene |
| 02/15/1996 | CA2328638A1 Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression |
| 02/15/1996 | CA2197770A1 Compositions for targeting materials to cells containing androgen receptors |
| 02/15/1996 | CA2196168A1 Recombinant virus vectors |
| 02/15/1996 | CA2195965A1 Hsv viral vector |
| 02/15/1996 | CA2195864A1 5'-dithio-modified oligonucleotides |
| 02/15/1996 | CA2194488A1 Method of using transdominant negative retroviral integrase in the treatment of retroviral infection |
| 02/14/1996 | EP0696206A1 Adenoviruses having modified fiber proteins |
| 02/14/1996 | EP0696205A1 Use of neuro-derived fetal cell lines for transplantation therapy |
| 02/14/1996 | EP0696200A1 Encapsulation of nucleic acids with conjugates that facilitate and target cellular uptake and gene expression |
| 02/14/1996 | EP0696191A1 Particulate vector and pharmaceutical composition containing such vector |
| 02/13/1996 | US5491133 Contacting eukaryotic cell in vitro with oligodeoxynucleotide which has complementarity for and is hybridizable to specifed messenger rna region and has modified phosphodiester linkage resistant to exonuclease degradation |
| 02/13/1996 | US5491073 Cloning of chicken anaemia DNA |
| 02/09/1996 | CA2155496A1 Nucleic acid-binding oligomers for therapy and diagnosis |
| 02/08/1996 | WO1996003515A2 Surface expression of enzyme in gene directed prodrug therapy |
| 02/08/1996 | WO1996003510A1 A polynucleotide herpes virus vaccine |
| 02/08/1996 | WO1996003508A1 Dna encoding ovine adenovirus (oav287) and its use as a viral vector |
| 02/08/1996 | WO1996003414A1 Antimessenger oligonucleotides and urokinase receptor reversion of the invasive phenotype of transformed human fibroblasts by antimessenger oligonucleotide inhibition of urokinase receptor gene expression |
| 02/08/1996 | WO1996003152A1 Antisense oligonucleotides against hepatitis b viral replication |
| 02/08/1996 | WO1996003151A2 Intracellular expression of carboxypeptidase g2 in enzyme prodrug therapy |
| 02/08/1996 | WO1996003146A1 Retroviral transduction of cells using soluble complement inhibitors |
| 02/08/1996 | WO1996003043A1 Human brain specific kinase |
| 02/08/1996 | WO1995026983A3 Treatment or diagnosis of abnormal signal transduction disorders |
| 02/08/1996 | WO1995022611A3 Methods and compositions for stimulating bone cells |